3.1.1 Interferon Monotherapy

At one time, Interferon alone was considered standard therapy. It is now used alone only when the patient has some condition, such as a heart problem, that doesn’t allow the use of ribavirin.

Nautilus Biotech is developing a set of improved IFN-alpha molecules with a longer half-life, without using pegylation technology. Patents have been applied for, and funding seems to be in place www.nautilusbiotech.com).